Thus, liquid biopsies are widely used in the clinical biomarker screening of tumors, such as endometrial cancer,122 lung cancer,123 pancreatic cancer,124 CRC,125 melanoma,126 renal cell carcinoma (RCC),127 breast cancer, ovarian cancer, cervical cancer, and bladder cancer.128 In addition, liquid biopsy technology is also utilized to detect and monitor KRAS, BRAF, and EGFR mutations in patients with lung cancer, CRC, and breast cancer.128. This evidence concerns the gene BRAF and breast carcinoma.